Skip to main content

Diagnosis and Treatment of Depression in Parkinson’s Disease

  • Chapter
Mental and Behavioral Dysfunction in Movement Disorders

Abstract

Depression and anxiety are the most common and frequently disabling psychiatric conditions that accompany Parkinson’s disease (PD). Although James Parkinson, in his original report of six patients, wrote that the “senses and intellect being uninjured” (1), he still used descriptions like “melancholy” and “unhappy sufferer.” In early 1920s, some authors argued that “abnormal psychic functioning” was a part of the disease process and that “the mental set was always depressive” (2). Nowadays, it is widely accepted that, despite discrepancies in patient selection, inconsistent definitions of depression, and different methods of assessment, a considerable risk of depression appears to accompany PD. Depressive symptoms in parkinsonian patients have been classified as “organic mood syndrome” in the Diagnostic and Statistical Manual of Mental Disorders, third edition, revised (DSM-IIIR) and as “mood disorder due to a general medical condition” in DSM-IV. Although the exact etiology of depression in PD is unclear, available evidence suggests that biochemical changes, psychosocial factors, and situational stressors may all contribute to its development (3). Finally, although major depression (MD) may occur in PD, studies indicate that the majority of depressed parkinsonians have less severe forms such as minor depression, dysthymic disorder, and subsyndromal forms (4–6).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Parkinson, J. (1817) An Essay on the Shaking Palsy Sherwood, Neely and Jones, London.

    Google Scholar 

  2. Jackson, J.A., Free, G.B.M., and Pike, H.V. (1923) The psychic manifestations in paralysis agitans, Arch. Neurol. 10, 680–684.

    Article  Google Scholar 

  3. Zesiewicz, T.A., Gold, M., Chari, G., and Hauser, R.A. (1999) Current issues in depression in Parkinson’s disease. Am. J. Geriatr. Psychiatry 7, 110–118.

    PubMed  CAS  Google Scholar 

  4. Tandberg, E., Larsen, J.P., Aarsland, D., and Cummings, J.L. (1996) The occurrence of depression in Parkinson’s disease: the community based study. Arch. Neurol. 53, 175–179.

    Article  PubMed  CAS  Google Scholar 

  5. Liu, C.-Y., Wang, S.-J., Fuh, J.-L., Lin, C.-H., Yang Y.-Y., and Liu, H.-C. (1997) The correlation of depression with functional activity in Parkinson’s disease. J. Neurol. 244, 493–498.

    Article  PubMed  CAS  Google Scholar 

  6. Starkstein, S.E., Petricca, G., Shemerinski, E., et al. (1998) Depression in classic versus akinetic-rigid Parkinson’s disease. Mov. Disord. 13, 29–33.

    Article  PubMed  CAS  Google Scholar 

  7. Klaassen, T., Verhey, F.R., Sneijders, G.H., Rozendaal, N., de Vet, H.C., and van Praag, H.M. (1995) Treatment of depression in Parkinson’s disease: a meta-analysis. J. Neuropsychiatry Clin. Neurosci. 7, 281–286.

    PubMed  CAS  Google Scholar 

  8. Gotham, A.M., Brown, R.G., and Marsden, C.D. (1986) Depression in Parkinson’s disease: a quantitative and qualitative analysis. J. Neurol. Neurosurg. Psychiatry 49, 381–389.

    Article  PubMed  CAS  Google Scholar 

  9. Cummings, J.L. (1992) Depression in Parkinson’s disease: a review. Am. J. Psychiatry 149, 443–454.

    PubMed  CAS  Google Scholar 

  10. Kostić, V.S., Filipović, S.R., Lečić, D., Momcilovic, D., Sokic, D., and Sternić, N. (1994) Effect of age at onset on frequency of depression in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 57, 1265–1267.

    Article  PubMed  Google Scholar 

  11. Giladi, N., Treves, T.A., Paleacu, D., et al. (2000) Risk factors for dementia, depression and psychosis in longstanding Parkinson’s disease. J. Neural. Transm. 107, 59–71.

    Article  PubMed  CAS  Google Scholar 

  12. Caap-Ahlgren, M. and Dehlin, O. (2001) Insomnia and depressive symptoms in patients with Parkinson’s disease— relationship to health-related quality of life. An interview study of patients living at home. Arch. Gerontol. Geriatr. 32, 23–33.

    Article  PubMed  Google Scholar 

  13. Doonief, G., Mirabello, E., Bell, K., Marder, K., Stern, Y., and Mayeux, R. (1992) An estimate of the incidence of depression in idiopathic Parkinson’s disease. Arch. Neurol. 49, 305–307.

    Article  Google Scholar 

  14. Hantz, P., Caradoc-Davies, G., Caradoc-Davies, T., Weatherall, M., and Dixon, G. (1994) Depression in Parkinson’s disease. Am. J. Psychiatry 151, 1010–1014.

    PubMed  CAS  Google Scholar 

  15. Aarsland, D., Larsen, J.P., Lim, N.G., et al. (1999) Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 67, 492–496.

    Article  PubMed  CAS  Google Scholar 

  16. Schrag, A., Jahanshahi, M., and Quinn, N.P. (2001) What contributes to depression in Parkinson’s disease? Psychol. Med. 31, 65–73.

    Article  PubMed  CAS  Google Scholar 

  17. Brown, R. and Jahanshahi, M. (1995) Depression in Parkinson’s disease: a psychosocial viewpoint. Adv. Neurol. 65, 61–84.

    PubMed  CAS  Google Scholar 

  18. Henderson, R., Kurlan, R., and Kersun, J.M. (1992) Preliminary examination of the comorbidity of anxiety and depression in Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci. 4, 257–264.

    PubMed  CAS  Google Scholar 

  19. Menza, M.A., Robertson-Hoffman, D.E., and Bonapace, A.S. (1993) Parkinson’s disease and anxiety: comorbidity with depression. Biol. Psychiatry 34, 465–470.

    Article  PubMed  CAS  Google Scholar 

  20. Walsh, K. and Bennett, G. (2001) Parkinson’s disease and anxiety. Postgrad. Med. J. 77, 89–93.

    Article  PubMed  CAS  Google Scholar 

  21. Shiba, M., Bower, J.H., Maraganore, D.M., et al. (2000) Anxiety disorders and depressive disorders preceding Parkinson’s disease: a case-control study. Mov. Disord. 15, 669–677..

    Article  PubMed  CAS  Google Scholar 

  22. Rabinstein, A.A. and Shulman, L.M. (2001) Management of behavioral and psychiatric problems in Parkinson’s disease. Parkinsonism Rel. Disord. 7, 41–50.

    Article  Google Scholar 

  23. American Psychiatric Association. (1994) Diagnostic and statistical manual or mental disorders (4tn ed.). wasnington, DC, APA.

    Google Scholar 

  24. Melamed, E. (1997) Neurobehavioral abnormalities in Parkinson’s disease, in Movement Disorders: Neurologic Principles and Practice (Watts, R.L. and Koller, W.C., eds.), McGraw-Hill, New York, pp. 257–262.

    Google Scholar 

  25. Shulman, L.M., Leifert, R., Singer, C., and Weiner, W.J. (1997) The diagnostic accuracy ot neurologists tor anxiety, depression, fatigue, and sleep disorders in Parkinson’s disease [abstract]. Mov. Disord. 12, 127.

    Article  Google Scholar 

  26. Sutor, B., Rummans, T.A., Jowsey, S.G., et al. (1998) Major depression in medically ill patients. Mayo Clin. Proc. 73, 329–337.

    Article  PubMed  CAS  Google Scholar 

  27. Starkstein, S.E., Preziosi, T.J., Bolduc, P.L., and Robinson, R.G. (1990) Depression in Parkinson’s disease. J. Nerv. Ment. Dis. 178, 27–31.

    Article  PubMed  CAS  Google Scholar 

  28. Vallderiolla, F., Nobbe, F.A., and Tolosa, E. (1997) Treatment of behavioral disturbances in Parkinson’s disease. J. Neural. Transm. 51, 175–204.

    Article  Google Scholar 

  29. Starkstein, S.E., Preziosi, T.J., Forrester, A.W., and Robinson, R.G. (1990) Specificity of affective and autonomic symptoms of depression in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 53, 869–873.

    Article  PubMed  CAS  Google Scholar 

  30. Marinković, Z., Kostić, V.S., Sternié, N., and Marinković, S. (1990) Pain in Parkinson’s disease. Serb. Arch. 118, 459–462.

    Google Scholar 

  31. Menza, M.A. and Rosen, R.C. (1995) Sleep in Parkinson’s disease: the role of depression and anxiety. Psychosomatics 36, 262–266.

    Article  PubMed  CAS  Google Scholar 

  32. Kostid, V.S., Šušid, V., Przedborski, S., and Sternié, N. (1991) Sleep EEG in depressed and nondepressed patients with Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci. 3, 99–103.

    Google Scholar 

  33. Friedman, J. and Friedman, H. (1993) Fatigue in Parkinson’s disease. Neurology 43, 2016–2018.

    Article  PubMed  CAS  Google Scholar 

  34. Hoogendijk, W.J.G., Sommer, I.E.C., Tissingh, G., Deeg, D.J.H., and Wolters, E.C. (1998) Depression in Parkinson’s disease. Psychosomatics 39, 416–421.

    Article  PubMed  CAS  Google Scholar 

  35. Cantello, R., Gilli, M., Riccio, A., and Bergamasco, B. (1986) Mood changes associated with end-of-dose-deterioration in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 49, 1182–1190.

    Article  PubMed  CAS  Google Scholar 

  36. Levin, B.E., Llabre, M.M., and Weiner, W.J. (1988) Parkinson’s disease and depression: psychometric properties or the Beck Depression Inventory. J. Neurol. Neurosurg. Psychiatry 51, 1401–1404.

    Article  PubMed  CAS  Google Scholar 

  37. Leentjens, A.F.G., Verhey, F.R.J., Luijckx, G.-J., and Troost, J. (2000) The validity of the Beck Depression inventory as a screening and diagnostic instrument for depression in patients with Parkinson’s disease. Mov. Disord. 15, 1221–1224.

    Article  PubMed  CAS  Google Scholar 

  38. Leentjens, A.F.G., Verhey, F.R.J., Lousberg, R., Spitsbergen, H., and Wilmink, F.W. (2000) The validity of the Hamilton and Montgomery-Asberg Depression Rating Scales as screening and diagnostic instrument for depression in patients with Parkinson’s disease. Int. J. Geriatr. Psychiatry 15, 644–649.

    Article  PubMed  CAS  Google Scholar 

  39. Cole, S.A., Woodard, J.L., Juncos, J.L., Kogos, J.L., Youngstrom, E.A., and Watts, R.L. (1996) Depression and disability in Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci. 8, 20–25.

    PubMed  CAS  Google Scholar 

  40. Starkstein, S.E., Mayberg, H.S., Leiguarda, R., Preziosi, T.J., and Robinson, R.G. (1992) A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 55, 377–382.

    Article  PubMed  CAS  Google Scholar 

  41. Tom, T. and Cummings, J.L. (1998) Depression in Parkinson’s disease: pharmacological characteristics and treatment. Drugs Aging 12, 55–74.

    Article  PubMed  CAS  Google Scholar 

  42. Marder, K., Tang, M.X., Cote, L., Stern, Y., and Mayeux, R. (1995) The frequency and associated risx factors for dementia in patients with Parkinson’s disease. Arch. Neurol. 52, 695–701.

    Article  PubMed  CAS  Google Scholar 

  43. Karlsen, K.H., Larsen, J.P., Tandberg, E., and Maeland, J.G. (1999) Influence of clinical and demographic variables on quality of life in patients with Parkinson’s disease. Neurol. Neurosurg. Psychiatry 66, 431–435.

    Article  CAS  Google Scholar 

  44. Kuopio, A.-M., Martilla, R.J., Helenius, H., Toivonen, M., and Rinne, U.K. (2000) The quality of lite in Parkinsons disease. Mov. Disord. 15, 216–223.

    Article  PubMed  CAS  Google Scholar 

  45. Lasser, R., Siegel, E., Dukoff, R., and Sunderland, T. (1998) Diagnosis and treatment or geriatric depression. CNS Drugs 9, 17–30.

    Google Scholar 

  46. Richard, I.H. and Kurlan, R. (1997) A survey of antidepressant drug use in Parkinson’s disease. Neurology 49, 1168–1170.

    Article  PubMed  CAS  Google Scholar 

  47. Maricle, R.A., Nutt, J.G., Valentine, R.J., and Carter, J.H. (1995) Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson’s disease: a double-blind, placebo-controlled study. Neurology 45, 1757–1760.

    Article  PubMed  CAS  Google Scholar 

  48. Yahr, M.D., Duvoisin, R.C., Schear, M.J., Barrett, R.E., and Hoehn, M.M. (1969) Treatment of parkinsonism with levodopa. Arch. Neurol. 21, 343–354.

    Article  PubMed  CAS  Google Scholar 

  49. Damasio, A.R., Antunes, J.L., and Macedo, C. (1970) L-dopa, parkinsonism, and depression. Lancet 2, 611–612.

    Article  PubMed  CAS  Google Scholar 

  50. Marsh, G.G. and Markham, C.H. (1973) Does levodopa alter depression and psychopathology in parkinsonism patients? J. Neurol. Neurosurg. Psychiatry 36, 925–935.

    Article  PubMed  CAS  Google Scholar 

  51. Growdon, J.H., Kieburtz, K., McDermott, M.P., Panisset, M., and Friedman, J.H. (1998) Levodopa improves motor function without impairing cognition in mild non-demented Parkinson’s disease patients. Parkinson Study Group. Neurology 50, 1327–1331.

    Article  PubMed  CAS  Google Scholar 

  52. Choi, C., Sohn, Y.H., Lee, J.H., and Kim, J.-S. (2000) The effect of long-term levodopa therapy on depression in de novo patients with Parkinson’s disease. J. Neurol. Sci. 172, 12–16.

    Article  PubMed  CAS  Google Scholar 

  53. Vazquez, A., Jimenez-Jimenez, FJ., Garcia-Ruiz, P., and Garcia-Urra, D. (1993) “Panic attacks” in Parkinson’s disease: a long-term complication of levodopa therapy. Acta Neurol. Scand. 87, 14–18.

    Google Scholar 

  54. Theohar, C., Fischer-Cornelssen, K., Akesson, H.O., Ansari, H., Gerlach, J., and Harper, P. (1981) Bromocriptine as antidepressant: double-blind comparative study with imipramine in psychogenic and endogenous depression. Curr. Ther. Res. 30, 830–842.

    Google Scholar 

  55. Inoue, T., Tsuchiya, K., Miura, J., et al. (1996) Bromocriptine treatment of tricyclic and heterocyclic antidepressantresistant depression. Biol. Psychiatry 40, 151–153.

    Article  PubMed  CAS  Google Scholar 

  56. MacGrath, P.J., Quitkin, F.M., and Klein, D.F. (1995) Bromocriptine treatment of relapses seen during selective serotonin re-uptake inhibitor treatment of depression. J. Clin. Psychopharmacol. 15, 289–291.

    Article  Google Scholar 

  57. Jouvent, R., Abensour, P., Bonnet, A.M., Widlocher, D., Agid, Y., and Lhermitte, F. (1983) Antiparkinsonian and antidepressant effects of high doses bromocriptine. J. Affect. Disord. 5, 141–145.

    Article  PubMed  CAS  Google Scholar 

  58. Factor, S.A., Molho, E.S., Podskalny, G.D., and Brown, D. (1995) Parkinson’s disease: drug-induced psychiatric states. Adv. Neurol. 65, 115–138.

    PubMed  CAS  Google Scholar 

  59. Przedborski, S., Liard, A., and Hildebrand, J. (1992) Induction of mania by apomorphine in a depressed parkinsonian patient. Mov. Disord. 7, 285–287.

    Article  PubMed  CAS  Google Scholar 

  60. Sporn, J., Gnaemi, S.N., Sambur, M.R., et al. (2000) Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann. Clin. Psychiatry 12, 137–140.

    Article  PubMed  CAS  Google Scholar 

  61. Corrigan, M.H., Denahan, A.Q., Wright, C.E., Ragual, R.J., and Evans, D.L. (2000) Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depression Anxiety 11, 58–65.

    Article  CAS  Google Scholar 

  62. Flaherty, J.A. and Bellur, S.N. (1981) Mental side effects of amantadine therapy: its spectrum and characteristics in a normal population. J. Clin. Psychiatry 42, 344–345.

    PubMed  CAS  Google Scholar 

  63. Dietrich, D.E., Bode, L., Spannhuth, C.W., et al. (2000) Amantadine in depressive patients with Borna disease virus (BDV) infection: an open trial. Bipolar Disord. 2, 65–70.

    Article  PubMed  CAS  Google Scholar 

  64. Moreau, J.L., Borgulya, J., Jenck, F., and Martin, J.R. (1994) Tolcapone: a potential new antidepressant detected in a novel animal model of depression. Behav. Pharmacol. 5, 344–350.

    Article  PubMed  CAS  Google Scholar 

  65. Fava, M., Rosenbaum, J.F., Kolsky, A.R., et al. (1999) Open study of the catechol-O-methyltransferase inhibitor tolacapone in major depressive disorder. J. Clin. Psychopharmacol. 19, 329–335.

    Article  PubMed  CAS  Google Scholar 

  66. Bresa, G.M. (1994) S-adenosyl-L-methionine as antidepressant: a meta analysis of clinical studies. Acta Neurol. Scand. 154(Suppl), 7–14.

    Article  Google Scholar 

  67. Di Rocco, A., Rogers, J.D., Brown, R., Werner, P., and Bottiglieri, T. (2000) S-adenosyl-methionine improves depression in patients with Parkinson’s disease in an open-label clinical trial. Mov. Disord. 15, 1225–1229.

    Article  PubMed  Google Scholar 

  68. Bejjani, B.-P., Damier, P., Arnulf, I., et al. (1999) Transient acute depression induced by high-frequency deep-brain stimulation. N. Engl. J. Med. 340, 1476–1480.

    Article  PubMed  CAS  Google Scholar 

  69. Bezerra, M.L.S., Martinez, J.-V.L., and Nasser, J.A. (1999) Transient acute depression induced by high-frequency deep-brain stimulation [correspondence]. N. Engl. J. Med. 340, 1003–1004.

    Google Scholar 

  70. Ghika, J., Ghika-Schmid, F., Fankhauser, H., et al. (1999) Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson’s disease: neuropsychological and neurological side effects. Report of four cases and review of the literature. J. Neurosurg. 91, 313–321.

    Article  PubMed  CAS  Google Scholar 

  71. Straits-Toster, K., Fields, JA., Wilkinson, S.B., et al. (2000) Health-related quality of life in Parkinson’s disease after pallidotomy and deep brain stimulation. Brain Cogn. 42, 399–416.

    Article  Google Scholar 

  72. Bakish, D., Habib, R., and Hooper, C.L. (1998) Mixed anxiety and depression: diagnosis and treatment options. CNS Drugs 9, 271–180.

    Article  CAS  Google Scholar 

  73. Denmark, J.C., David, J.D.P., and McComb, S.G. (1961) Imipramine hydrochloride (Tofranil) in parkinsonism: a preliminary report. Br. J. Clin. Pract. 15, 523–524.

    PubMed  CAS  Google Scholar 

  74. Strang, R.R. (1965) Imipramine in treatment of parkinsonism: a double-blind placebo study. BMJ 2, 33–34.

    Article  PubMed  CAS  Google Scholar 

  75. Laitinen, L. (1969) Desipramine in treatment of parkinson’s disease: a placebo-controlled study. Acta Neurol. Scand. 45, 109–113.

    Article  PubMed  CAS  Google Scholar 

  76. Andersen, J., Aabro, E., Gulmann, N., Hjelmsted, A., and Pedersen, H.E. (1980) Antidepressive treatment in Parkinson’s disease. Acta Neurol. Scand. 62, 210–219.

    Article  PubMed  CAS  Google Scholar 

  77. Indaco, A. and Carrieri, P.D. (1988) Amitryptiline in the treatment of headache in patients with Parkinson’s disease. Neurology 38, 1720–1722.

    Article  PubMed  CAS  Google Scholar 

  78. Cummings, J.L. and Masterman, D.A. (1999) Depression in patients with Parkinson’s disease. Int. J. Geriatr. Psychiatry 14, 711–718.

    Article  PubMed  CAS  Google Scholar 

  79. Cunningham, L.A. (1994) Depression in medically ill: choosing an antidepressant. J. Clin. Psychiatry 55(Suppl. A), 98–100.

    Google Scholar 

  80. Meara, R.J., Bhowmick, B.K., and Hobson, J.P. (1996) An open uncontrolled study of the use of sertraline in the treatment of depression in Parkinson’s disease. J. Serotonin Res. 4, 243–249.

    Google Scholar 

  81. Hauser, R.A. and Zesiewicz, T.A. (1997) Sertraline for the treatment of depression in Parkinson’s disease. Mov. Disord. 12, 756–757.

    Article  PubMed  CAS  Google Scholar 

  82. Wittgens, W., Donath, O., and Trenckmann, U. (1997) Treatment of depressive syndromes in Parkinson’s disease with paroxetine [abstract]. Mov. Disord. 12, 128.

    Google Scholar 

  83. Ceravolo, R., Nuti, A., Piccinni, A., et al. (2000) Paroxetine in Parkinson’s disease: effects on motor and depressive symptoms. Neurology 55, 1216–1218.

    Article  PubMed  CAS  Google Scholar 

  84. McCance-Katz, E.F., Marek, K.L., and Price, L.H. (1992) Serotonergic dysfunction in depression associated with Parkinson’s disease. Neurology 42, 1813–1814.

    Article  PubMed  CAS  Google Scholar 

  85. Mayeux, R., Stern, Y., Sano, M., Williams, J.B., and Cote, L.J. (1988) The relationship of serotonin to depression in Parkinson’s disease. Mov. Disord. 3, 237–244.

    Article  PubMed  CAS  Google Scholar 

  86. Kostić, V.S., Djuričić, B.M., ternié, N., Bumbaširević, L.J., Nikolié, M., and Mršulja, B.B. (1987) Depression and Parkinson’s disease: possible role of serotonergic mechanisms. J. Neurol. 234, 94–96.

    Article  PubMed  Google Scholar 

  87. Kostié, V.S., Lečić, D., Doder, M., Marinković, J., and Filipović, S. (1996) Prolactine and cortisol responses to fenfluramine in Parkinson’s disease. Biol. Psychiatry 40, 769–775.

    Article  Google Scholar 

  88. Chouinard, G. and Sultan, S. (1992) A case of Parkinson’s disease exacerbated by fluoxetine. Hum. Psychopharmacol. 7, 63–66.

    Article  Google Scholar 

  89. Jansen-Steur, E.N.H. (1993) Increase of Parkinson disability after fluoxetine medication. Neurology 43, 211–213.

    Article  Google Scholar 

  90. Jimenez-Jimenez, F.J., Tejeiro, J., Martinez-Junquera, G., et al. (1994) Parkinsonism exacerbated by paroxetine [letter]. Neurology 44, 2406.

    Article  PubMed  CAS  Google Scholar 

  91. Linazasoro, G. (2000) Worsening of Parkinson’s disease by citalopram. Parkinsonism Rel. Disord. 6, 111–113.

    Article  Google Scholar 

  92. Gerber, P.E. and Lynd, L.D. (1998) Selective serotonin-reuptake inhibitor-induced movement disorders. Ann. Pharmacother. 32, 692–698.

    Article  PubMed  CAS  Google Scholar 

  93. Gobert, A., Rivet, J.-M., Lejeune, F., et al. (2000) Serotonin 2c receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse 36, 205–221.

    Article  PubMed  CAS  Google Scholar 

  94. Montastruc, J.L., Fabre, N., and Blin, O. (1995) Does fluoxetine aggravate Parkinson’s disease? A pilot prospective study. Mov. Disord. 10, 355–356.

    Article  PubMed  CAS  Google Scholar 

  95. Caley, C.F. and Friedman, J.H. (1992) Does fluoxetine exacerbate Parkinson’s disease? J. Clin. Psychiatry 53, 278–282.

    PubMed  CAS  Google Scholar 

  96. Richard, I.H., Maughn, A., and Kurlan, R. (1999) Do serotonin reuptake inhibitor worsen Parkinson’s disease? A retrospective case series. Mov. Disord. 14, 155–157.

    Article  PubMed  CAS  Google Scholar 

  97. Tesei, S., Antonini, A., Canesi, M., Zecchinalli, A., Mariani, C.B., and Pezzoli, G. (2000) Tolerability of paroxetine in Parkinson’s disease: a prospective study. Mov. Disord. 15, 986–989.

    Article  PubMed  CAS  Google Scholar 

  98. Toyama, S.C. and Iakono, R.P. (1994) Is it safe to combine a selective serotonin reuptake inhibitor with selegiline? Ann. Pharmacother. 28, 405–406.

    PubMed  CAS  Google Scholar 

  99. Waters, C.H. (1994) Fluoxetine and selegiline. Can. J. Neurol. Sci. 21, 259–261.

    PubMed  CAS  Google Scholar 

  100. Richard, I., Kurlan, R., Tanner, C., Factor, S., Hubble, J., Suchowersky, 0., and Waters, C. (1997) Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease: Parkinson Study Group. Neurology 48, 1070–1077.

    Article  PubMed  CAS  Google Scholar 

  101. Keller, M.B. and Hanks, D.L. (1995) Anxiety symptom relief in depression treatment outcomes. J. Clin. Psychiatry 56(Suppl. 6), 22–29.

    PubMed  Google Scholar 

  102. Hoffman, W.F. (1985) Treatment of major depression and Parkinson’s disease with combined phenelzine and amantadine [letter]. Am. J. Psychiatry 142, 273.

    Google Scholar 

  103. Hargrave, R. and Ashford, J.W. (1992) Phenelzine treatment of depression in Parkinson’s disease. Am. J. Psychiatry 149, 1751–1752.

    PubMed  CAS  Google Scholar 

  104. Brown, A.S. and Gershon, S. (1993) Dopamine and depression. J. Neural. Transm. 91, 75–109.

    Article  CAS  Google Scholar 

  105. Fahn, S. and Chouinard, S. (1998) Experience with tranylcypromine in early Parkinson’s disease. J. Neural. Transm. 52(Suppl.), 49–61.

    Article  CAS  Google Scholar 

  106. Sunderland, T., Cohen, R.M., Molchan, S., et al. (1994) High-dose selegiline in treatment-resistant older depressive patients. Arch. Gen. Psychiatry 51, 607–615.

    Article  PubMed  CAS  Google Scholar 

  107. Mann, J.J., Aarons, S.F., Wilner, P.J., et al. (1989) A controlled study of the antidepressant efficacy and side-effects of (-)-deprenyl: a selective monoamino oxidase inhibitor. Arch. Gen. Psychiatry 46, 45–50.

    Article  PubMed  CAS  Google Scholar 

  108. Kuhn, W. and Muller, T. (1996) The clinical potential of deprenyl in neurologic and psychiatric disorders. J. Neural. Transm. 48, 85–93.

    CAS  Google Scholar 

  109. Allain, H., Pollak, P., and Neukirch, H.C. (1993) Symptomatic effect of selegiline in de novo parkinsonian patients: the French Selegiline Multicenter Trial. Mov. Disord. 8(Suppl. 1), S36–540.

    Article  PubMed  Google Scholar 

  110. Parkinson Study Group. (1989) Effect of deprenyl on the progression of disability in early Parkinson’s disease. N. Engl. J. Med. 321, 1364–1371.

    Article  Google Scholar 

  111. Ritter, J.L. and Alexander, B. (1997) Retropsective study of selegiline-antidepressant drug interactions and a review of the literature. Ann. Clin. Psychiatry 9, 7–13.

    Article  PubMed  CAS  Google Scholar 

  112. Angst, J. and Stabl, M. (1992) Efficacy of moclobemide in different patient groups: a meta-analysis of studies. Psychopharmacology 106(Suppl.), S109–S113.

    Article  PubMed  Google Scholar 

  113. Bakish, D., Saxena, B.M., Bowen, R., and D. Souza, J. (1993) Reversible monoamine oxidase A inhibitors in panic disorders. Clin. Neuropharmacol. 16(Suppl. 2), 77–82.

    Google Scholar 

  114. Takats, A., Tarczy, N., Simo, M., Szombathely, E., Bodrogi, A., and Karpati, R. (1994) Moclobemide treatment in Parkinson’s disease with depression. New Trends Clin. Neuropharmacol. 8, 260.

    Google Scholar 

  115. Jansen-Steur, E.N.H. and Ballering, L.A.P. (1997) Moclobemide and selegiline in the treatment of depression in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 63, 547–548.

    Article  Google Scholar 

  116. Sieradzan, K., Channon, S., Ramponi, C., Stern, G.M., Lees, A.J., and Youdim, M.B.H. (1995) The therapeutic potential of moclobemide, a selective monoamine oxidase A inhibitor in Parkinson’s disease. J. Clin. Psychopharmacol. 15(Suppl. 2), 51–59.

    Article  Google Scholar 

  117. Sternić, N., Kacar, A., Filipović, S., Svetel, M., and Kostić, V.S. (1998) The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson’s disease. Clin. Neuropharmacol. 21, 93–96.

    Google Scholar 

  118. Silver, J.M. and Yudofski, S.C. (1992) Drug treatment of depression in Parkinson’s disease, in Parkinson’s Disease: Neurobehavioral Aspects (Huber, S.J. and Cummings, J.L., eds.), Oxford University Press, New York, pp. 240–254.

    Google Scholar 

  119. Goetz, C.G., Tanner, C.M., and Klawans, H.L. (1984) Bupropion in Parkinson’s disease. Neurology 34, 1092–1094.

    Article  PubMed  CAS  Google Scholar 

  120. Kanner, A.M. (2000) The treatment of depression in various neurological disorders. Syllabi of AAN 4TP.003, 18–30.

    Google Scholar 

  121. Leentjens, A.F., Verhey, F.R., and Vreeling, F.W. (2000) Successful treatment of depression in a Parkinson disease patient with bupropion. Ned. Tijdschr. Geneeskd. 144, 2157–2159.

    PubMed  CAS  Google Scholar 

  122. Kent, J.M. (2000) SnaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 355, 911–918.

    Article  PubMed  CAS  Google Scholar 

  123. Gorman, J.M. (1999) Mirtazapine: clinical overview. J. Clin. Psychiatry 60(Suppl. 17), 9–13.

    PubMed  CAS  Google Scholar 

  124. Fawcett, J. and Barkin, R.L. (1998) Review of the results from the clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J. Affect. Disord. 51, 267–285.

    Article  PubMed  CAS  Google Scholar 

  125. Pact, V. and Giduz, T. (1999) Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias. Neurology 53, 1154.

    Article  PubMed  CAS  Google Scholar 

  126. Douyon, R., Serby, M., Klutchko, B., and Rotrosen, J. (1989) ECT and Parkinson’s disease revisited: a naturalistic study. Am. J. Psychiatry 146, 1452–1455.

    Google Scholar 

  127. Faber, R. and Trimble, M. (1991) Electroconvulsive therapy in Parkinson’s disease and other movement disorders. Mov. Disord. 6, 293–303.

    Article  PubMed  CAS  Google Scholar 

  128. Moellentine, C., Rummans, T., Ahlskog, J.E., et al. (1998) Effectiveness of ECT in patients with parkinsonism. J. Neuropsychiatry Clin. Neurosci. 10, 187–193.

    PubMed  CAS  Google Scholar 

  129. Wengel, S.P., Burke, W.J., Pfeiffer, R.F., Roccaforte, W.H., and Paige, S.R. (1998) Maintenance electroconvulsive therapy for intractable Parkinson’s disease. Am. J. Geriatr. Psychiatry 6, 263–269.

    PubMed  CAS  Google Scholar 

  130. George, M.S., Wassermann, E.M., Kimbrell, T.A., et al. (1997) Mood improvement following daily left prefrontal repetitive transcranial magnetic stimulation in patients with depression: a placebo-controlled crossover trial. Am. J. Psychiatry 154, 1752–1756.

    PubMed  CAS  Google Scholar 

  131. Klein, E., Kreinin, I., Chistyakov, A., et al. (1999) Therapeutic efficacy of right prefrontal slow repetitive transcranial magnetic stimulation in major depression: a double-blind controlled study. Arch. Gen. Psychiatry 56, 315–320.

    Article  PubMed  CAS  Google Scholar 

  132. Nobler, M.S., Sackeim, H.A., Prohovnik, I., et al. (1994) Regional cerebral blood flow in mood disorders III: treatment and clinical response. Arch. Gen. Psychiatry 51, 884–897.

    Article  PubMed  CAS  Google Scholar 

  133. Pascual-Leone, A., Catala, M.D., and Pascual, A.P. (1996) Lateralized effect of rapid-rate transcranial magnetic stimulation of prefrontal cortex on mood. Neurology 46, 499–502.

    Article  PubMed  CAS  Google Scholar 

  134. Mally, J. and Stone, T.W. (1999) Therapeutic and “dose-dependent” effect of repetitive microelectroshock induced by transcranial magnetic stimulation in Parkinson’s disease. J. Neurosci. Res. 57, 935–940.

    Article  PubMed  CAS  Google Scholar 

  135. George, M.S., Lisanby, S.H., and Sackeim, H.A. (1999) Transcranial magnetic stimulation: applications in neuropsychiatry. Arch. Gen. Psychiatry 56, 300–311.

    Article  PubMed  CAS  Google Scholar 

  136. Berger, M. and Riemann, D. (1993) Normal and abnormal REM sleep regulation: REM Sleep in depression-an overview. J. Sleep Res. 2, 211–223.

    Article  PubMed  Google Scholar 

  137. Demet, E.M., Chicz-Demet, A., Fallon, J.H., and Sokolski, K.N. (1999) Sleep deprivation therapy in depressive illness and Parkinson’s disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 23, 753–784.

    Article  PubMed  CAS  Google Scholar 

  138. Green, T.D., Reynolds, C.F., Mulsant, B.H., et al. (1999) Accelerating antidepressant response in geriatric depression: a post hoc comparison of combined sleep deprivation and paroxetine versus monotherapy with paroxetinem nortriptyline, or placebo. J. Geriatr. Psychiatry Neurol. 12, 67–71.

    Article  PubMed  CAS  Google Scholar 

  139. Perry, W., Benbow, C., West, L., and Rockwell, E. (1993) Sleep deprivation in an elderly man with Parkinson’s disease [letter. Am. J. Psychiatry 150, 350.

    PubMed  CAS  Google Scholar 

  140. Bertolucci, P.H., Andrade, L.A., Lima, J.G., and Carlini, E.A. (1987) Total sleep deprivation and Parkinson’s disease. Arq. Neuropsiqiatr. 45, 224–230.

    CAS  Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Kostić, V.S., Stefanova, E., Dragašević, N., Potrebić, S. (2003). Diagnosis and Treatment of Depression in Parkinson’s Disease. In: Bédard, MA., Agid, Y., Chouinard, S., Fahn, S., Korczyn, A.D., Lespérance, P. (eds) Mental and Behavioral Dysfunction in Movement Disorders. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-326-2_27

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-326-2_27

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-372-5

  • Online ISBN: 978-1-59259-326-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics